Idelalisib in Chronic Lymphocytic Leukemia
2 Views
administrator
07/08/23
The panelists, William G. Wierda, MD, PhD; Richard R. Furman, MD; and Alessandra Ferrajoli, MD, evaluate the role of idelalisib, a phosphoinositide 3-kinase inhibitor, in the treatment of chronic lymphocytic leukemia.
-
Category
Show more
Facebook Comments
No comments found